RecruitingPhase 2NCT07188090

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

A Prospective Trial Evaluating Plerixafor-based Mobilization and Risk of Engraftment Syndrome After Autologous Hematopoietic Stem Cell Transplantation

Sponsor

Thomas Jefferson University

Enrollment

100 participants

Start Date

Oct 16, 2025

Study Type

INTERVENTIONAL

Conditions

Hodgkin Lymphoma Non-Hodgkin Lymphoma Multiple Myeloma

Summary

This prospective trial investigates the approach of G-CSF with risk-adapted Plerixafor use for stem cell mobilization in patients undergoing autologous stem cell transplantation. Since FDA approval in 2008, Plerixafor has been combined with G-CSF to mobilize stem cells, though this regimen has been associated with a potentially higher incidence of engraftment syndrome. The trial aims to evaluate whether using G-CSF alone, with selective use of Plerixafor, can achieve adequate stem cell collection while possibly reducing the incidence of engraftment syndrome.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a medication called Mozobil (plerixafor) to help move stem cells from the bone marrow into the bloodstream before a stem cell transplant. The transplant uses your own stem cells (autologous), which are collected, then given back to you after high-dose chemotherapy. **You may be eligible if...** - You are 18 or older - You have multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin's lymphoma - You are scheduled to receive your own stem cells in a transplant - You have adequate heart, lung, liver, and kidney function - You previously received stem cell mobilization treatment with G-CSF with or without plerixafor **You may NOT be eligible if...** - You have uncontrolled HIV or a serious active bacterial infection - You have active cancer in the brain or spinal cord - You are pregnant or breastfeeding - You have another active cancer (other than certain skin cancers) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPlerixafor

Plerixafor is an antagonist of chemokine receptor-4 (CXCR4) receptor that can release stem cells from the bone marrow niche into the peripheral blood circulation

DRUGGcsf

All patients will receive G-CSF (peg-filgrastim or filgrastim) starting on day -4, prior to planned peripheral blood stem cell collection on day 0.

Locations(1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07188090

Related Trials

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

NCT06152575278 locations

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716128 locations

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT072593042 locations

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

NCT0582653534 locations

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT0629722652 locations